Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipilimumab Induction for Melanoma Brain Metastases
NCT02097732Phase 2Terminated
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Apr 2014
- Primary completion
- Aug 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ipilimumab in melanoma, sponsored by University of Michigan Rogel Cancer Center. Started Apr 2014; status: terminated.
02
Drugs
ipilimumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02097732.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02097732.